Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Contributed by: PR Newswire

Tags

LUNDBECK-FDA-EMA

More Like This

Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease

The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026

Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy

GlobeNewswire associated0

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma